ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with relapsed or refractory osteosarcoma and other sarcomas.

Trial Details

NCT ID
NCT05830123
Phase
PHASE2
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • HS-20093
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Changsha, China|28.19874,112.97087
  • Guangzhou, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25
  • Hangzhou, China|30.29365,120.16142

Key Eligibility Criteria

  • At least age of 18 years at screening;
  • Patients with histologically confirmed relapsed or refractory osteosarcoma or other sarcomas who have progressed upon first-line systemic treatment.
  • At least one measurable lesion according to RECIST 1.1.
  • Agree to provide fresh or archival tumor tissue and peripheral blood samples.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →